Join Class Action »
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
If you bought Zogenix securities between February 6, 2019 and April 8, 2019, and would like to join the action, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
New York, N.Y., April 17, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
To join the Zogenix class action, go to http://zhanginvestorlaw.com/cases/zogenix-inc/ or call Sophie Zhang, Esq. or toll-free at 800-991-3756 or email firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Zogenix’s New Drug Application (“NDA”) for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (2) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (3) as a result, Zogenix’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 11, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/zogenix-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at email@example.com.
Zhang Investor Law represents investors worldwide.